| |
Year:
2009
| Volume: 17
| Issue: 3-4
| Pages: 68-71
|
| |
Review Article |
| |
PROPHYLACTIC HPV VACCINES
Aljoša MAndic |
| |
DOI:
10.2298/AOO0904068M |
| |
Abstract: |
| |
Human papillomavirus (HPV) is one of the most common sexually transmitted diseases worldwide. Cervical and other anogenital cancers, cervical and anal intraepithelial neoplasia, genital warts, and recurrent respiratory papillomatosis are HPVassociated diseases. Prophylactic HPV vaccines are composed of HPV L1 capsid protein that self-assemble into virus-like particles (VLPs) when expressed in recombinant systems. Two types of prophylactic vaccines are designed as a bivalent vaccine to protect against high-risk HPV types 16 and 18 and a quadrivalent vaccine designed to protect against HPV 16 and 18, and low-risk, genital wart-causing HPV 6 and 11. Proof-of-principle trials have suggested that intramuscular injections of VLPs result in strong adaptive immune responses that are capable of neutralizing subsequent natural infections. Recent research on the safety and efficacy of candidate prophylactic vaccines against HPV have shown very promising results with nearly 100% efficacy in preventing the development of persistent infections and cervical precancerous lesions in vaccinated individuals. |
| |
Key words:
Papillomavirus Vaccines; Papillomavirus Infections; Cervical Intraepithelial Neoplasia |
| |
Read
full text in PDF [Full
Text] |
|
|